Carregant...
Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies
Background The recommended dose of rasburicase is quite expensive, thus limiting its use. Whether a lower dose of rasburicase would be equally effective for critically ill children, who often have more complicated situations and a higher risk of hospital death, is still unknown. Objective To explore...
Guardat en:
| Publicat a: | Int J Clin Pharm |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7603475/ https://ncbi.nlm.nih.gov/pubmed/32974856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11096-020-01144-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|